YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING

Size: px
Start display at page:

Download "YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING"

Transcription

1 YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING

2 THE NEW STANDARD OF CARE WHY GENETIC TESTING? Genetic testing makes it possible to know a priori how your patients will metabolize a specific drug. It is now extremely practical and cost effective to identify special biomarkers that affect how your individual patients will metabolize a broad array of prescribed drugs. Recent clinical studies reveal that approximately 50% of all people carry variant genes that will alter the rate they will metabolize or activate many commonly prescribed drugs used to treat cardiac disease (high blood pressure, chest pain/angina, irregular heart beats/arrhythmias, high cholesterol, blood clots/anticoagulants); manage pain (acute post-surgical or traumatic pain, chronic pain or generalized pain); treat neuropsychiatric disorders (anxiety, depression, seizures); treat gastric ulcers or reflux, and diabetes. Patients with gene variants are eight times more likely to experience an adverse drug reaction or lack of efficacy to their prescribed medication. IN-OFFICE GENETIC TESTING: SIMPLE, FAST AND ACCURATE Providing state-of-the-art genetic testing services in your office are simple to perform and easy to get started. All that is required is; 1) the physician orders the one-time study for the patient; 2) a nurse or PA obtains a patient specimen by taking a buccal swab from the inside of the patients cheek; and 3) the patient test sample is sent via PERSONALIZED MEDICINE: THE TIME IS NOW The use of modern pharmacogenomics enables clinicians to identify key genetic metabolic markers that determine their patient s metabolism and therapeutic response to a particular drug before prescribing a therapy. Molecular diagnostics are good for the patient, good for the practice and good for the healthcare system. Specific genes, chromosomes, enzymes and proteins determine drug response. MOLECULAR DIAGNOSTICS DEFINING TOOLS FOR A lab technologist prepares DNA sample for analysis. prepaid FEDX envelope to Genetisys s CLIA-accredited high complexity diagnostic laboratory (Bio Med Laboratory). A comprehensive genetics4you genotype panel evaluates a multitude of primary pharmacogenomic biomarkers and important inherited variants impacting metabolism or drug response using state-of-the-art microarray DNA analyzers. The patient s test results are provided electronically or via fax to the ordering physician in approximately one week. The ordering physician renders a professional interpretation of the patient s test results and defines a tailored or personalized treatment plan specific to an individual patient.

3 ARE THE MODERN MEDICINE. GENETIC TESTING REIMBURSMENT Genetic (molecular diagnostic and pharmacogenomic) tests are covered by Medicare, MediCAL and most major insurance carriers to evaluate a patient s ability to metabolize commonly used cardiovascular drugs. The FDA has issued a Black Box Warning on the Plavix label alerting patients that poor metabolizers are at greater risk for adverse cardiovascular events and informs them genetic testing can identify patients CYP2C19 metabolic function. Numerous clinical studies also demonstrate that CYP2C9, CYP2D6 or CYP3A4/3A5 variants can reduce metabolic function. Approximately 120 drugs now have the FDA Black Box Labeling. Molecular analysis reveals a patient s unique genetic signature.

4 YOUR PARTNER FOR PERSONALIZED MEDICINE GENETISYS THE QUALITY LEADER FOR IN-OFFICE GENETIC TESTING We are experts at bringing advanced molecular diagnostic testing services to physicians and their practices. Our focus is on delivering state-of-the-art diagnostic services with unequaled physician, staff and patient education; premier patient and referrer marketing materials; intuitive physician-friendly pharmacogenomic reports; and unmatched pharmacogenomic and interpretation support. With the growing body of literature supporting the use of genetic testing for a wide range inherited and pharmacogenomic applications its no surprise why everybody s talking about it. It s the reason many leading physicians are already embracing this technology and are distinguishing their practices today with the formal adoption of these new standards of care for their patients. WE MAKE IT EASY TO GET STARTED We provide the physician and their personnel all that is required to get started including comprehensive educational materials, genetic test requisition forms, patient informational materials, physician informational materials, informed patient consent forms, patient specimen collection kits, and prepaid test shipment kits. Genetisys oversee all start-up activities to ensure quality services are obtained consistently, right from the start. Premier Getting Starting Educational Programs In-Office Test Start-Up Procedures Patient DNA Specimen Collection & Shipment Kits Quality Patient and Referral Marketing Materials Comprehensive Genotype/Phenotype Test Results Intuitive Physician-Friendly Electronic Patient Reports Pharmacogenomic and Interpretation Support Responsive Local Support & Account Management WE PRIDE OURSELVES IN OUR ABILITY TO BRING LEADING EDGE CARE TO OUR PATIENTS YOUR EXPERT PARTNER IN GENETICS With more than 30 years of experience in molecular medicine and emerging technologies, Genetisys experts are uniquely qualified to get your practice set-up as a center of excellence for molecular diagnostic genetic testing. As your committed partner, we seek to keep our clients and their practices at the forefront in the use of the latest available in-office genetic tools and help to distinguish our client s clinical services by practicing Personalized Medicine The New Standards of Care. Pharmacogenomic testing make it possible to define the most effective drug therapy for an individual - the first time.

5 CARDIOLOGY CENTER OF EXCELLENCE MOLECULAR DIAGNOSTICS GENETIC TEST CENTER You have the opportunity to be at the forefront of this exciting medical revolution and distinguish your medical practice from your competitors. Genetisys makes it easy for your practice to be a quality provider for in-office genetic testing services simply and fast, with no capital investment. We will keep you informed of all the new opportunities to expand your in-office genetic testing portfolio as new tests become available. The time is now to differentiate your practice and start improving clinical outcomes for your patients by practicing the new standard of care afforded by genetic testing. As your partner, we make it effortless for you to Get Started. Patients are unique genetically and their care and treatment should be individualized.

6 YOUR CODE FOR PERSONALIZED MEDICINE genetics4you THE NEW STANDARD OF CARE The comprehensive genotyping test panel is typically performed on a person once in their lifetime to determine a patient s unique genetic blueprint, which can be used by the physician(s), over and over, as an important reference tool for choosing the most effective prescriptions or drug therapies, that produce the best clinical outcomes for individual patients. With the average Medicare patient seeing more than 6 physicians annually and those with chronic diseases over 10 physicians, choosing and managing a patient s drug therapies, and avoiding adverse drug-drug interactions is becoming increasingly important to optimizing overall patient care and outcomes. TYPES OF GENETIC TESTS There are two primary types of genetic tests available to patients, Molecular diagnostic testing, that identifies inherited genetic variants that predispose a patient to certain diseases; and pharmacogenomic testing which identifies a multitude of genetic biomarkers or variants that determine an individual s specific response to a broad array of drugs used to treat cardiac disease (Plavix, Coumadin, beta blockers, antiarrhythmics, CA channel blockers and statins), neuropsychiatric disorders (antidepressants, anti-seizure, migraines), gastric ulcers or reflux (PPI s), diabetes (sulfonylureas), and pain management (opioids, NSAIDs, benzodiazepines). More than 75% of the population have genetic variations that increase or decrease the availability of cytochrome enzymes that are heavily relied upon for drug metabolism and conversion. ONE-TIME TEST A LIFETIME OF BENEFITS The value of knowing your patient s genetic signature will enhance your ability to prescribe the most effective treatments for each patient; determine proper dosages of drugs based on predetermined patient-specific metabolic or inherited biomarkers; avoid serious drug-drug interactions and reduce the possibility of using drugs or dosages that could result in catastrophic adverse effects. A single genetics4you genotyping test, once in a lifetime that s all it takes to introduce personalized medicine to your patients and begin practicing a whole New Standard of Care. THE RIGHT DRUG, AT THE RIGHT PATIENT THAT S HIGH DIAGNOSTIC VALUE TODAY AND TOMORROW The genetics4you molecular diagnostic panel marks the start of a new era of personalized medicine for medical practices and patients. With hundreds of DNA tests under development that offer potential to identify a number of other inherited medical conditions, it is highly likely that diagnostic genetic tools will play an increasingly important role in optimizing patient care and outcomes. Genetic testing makes it possible to detect disease earlier, monitor a patient s response to therapy, and enables doctors to choose the right therapy for a patient the first time.

7 WHO DO I TEST? The genetics4you panel is extremely useful for assessing drug response in patients with cardiac disease; psychiatric disorders; acute, generalized or chronic pain; diabetes; gastric ulcers or reflux; as well as many other conditions. It s useful for determining the right drugs and dosage for every patient, prior to initiating drug therapy; for patients that have had adverse reactions to existing drugs or therapy; for patients you are having difficulty in obtaining the proper drug response, for patients with planned surgical or vascular inventions; and for patients who are on medications that have not been tested previously. One test benefits for a lifetime. RIGHT DOSE, FOR THE PERSONALIZED MEDICINE. A physician reviews the molecular diagnostic cardiac panel genotyping results with a patient and prescribes a tailored treatment plan based on their unique genetic signature.

8 THE NEW STANDARD OF CARE DISTINGUISH YOUR PRACTICE AND COMMITMENT TO YOUR PATIENTS We are proud to offer state-of-the-art genetic molecular diagnostic testing capabilities to all of our medical clients. Our conformance to the New Standards of Care afforded by what is called Personalized Medicine ensures that every patient receives the most effective treatment and care based on their individual genetic biomarkers that determine their inherent ability to respond to a particular drug or therapy. The First Choice For In-Office Genetic Testing Genetisys 149 W Lambert Road Brea, CA Phone: (858) Fax: (714) info@genetisysmdx.com Genetisys and genetics4you are trademarks of Genetisys Genetisys 03/13. Specifications or information subject to change at any time. Genetisys and Bio Med Laboratory are divisions of L&M Lab, Inc. REV201303

The future is. Personalized Medicine.

The future is. Personalized Medicine. The future is Personalized Medicine. What is Pharmacogenomics (PGx)? Pharmacogenomics and Personalized Medicine Patient Adherence Many commonly prescribed medications used to treat everyday ailments can

More information

Molecular Diagnostics. Castle Medical LLC.

Molecular Diagnostics. Castle Medical LLC. Molecular Diagnostics Castle Medical LLC. What is DNA testing? Pharmacogenomics is a scientific disciple that deals with the influence of patient s genotype on drug response. Objective: to deliver the

More information

Your story is unique. Diet & Exercise. Environment. Your health. Lifestyle. Genetics A PICTURE OF YOUR HEALTH

Your story is unique. Diet & Exercise. Environment. Your health. Lifestyle. Genetics A PICTURE OF YOUR HEALTH What s your story? Your story is unique It s a complex intersection of where you ve come from, and where your everyday choices are taking you. Optimal health choices for you might be different from others.

More information

Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association

Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Before the House Energy and Commerce Subcommittee on Health 21st Century Cures: Examining the Regulation of Laboratory

More information

Your genes. Your roadmap. Health TechNet & Pharmacogenomics (PGx) February 16, Franziska Moeckel AVP, Personalized Health

Your genes. Your roadmap. Health TechNet & Pharmacogenomics (PGx) February 16, Franziska Moeckel AVP, Personalized Health Your genes. Your roadmap. Health TechNet & Pharmacogenomics (PGx) February 16, 2018 Franziska Moeckel AVP, Personalized Health Your genes. Your roadmap. Overview Inova s Precision Medicine Journey MediMap

More information

Cytochrome P450 Genotype Panel

Cytochrome P450 Genotype Panel DOB: Age: Gender: Visit Number (FIN): Patient Results Client: Physician: ARUP Test Code: 2013098 Collection Date: 11/29/2016 Received in lab: 11/30/2016 Completion Date: 12/07/2016 Gene Genotype Phenotype

More information

GENETIC TESTING A Resource from the American College of Preventive Medicine

GENETIC TESTING A Resource from the American College of Preventive Medicine GENETIC TESTING A Resource from the American College of Preventive Medicine A Time Tool for Clinicians ACPM's Time Tools provide an executive summary of the most up-to-date information on delivering preventive

More information

Pharmacogenetics of Drug-Induced Side Effects

Pharmacogenetics of Drug-Induced Side Effects Pharmacogenetics of Drug-Induced Side Effects Hui - Ching Huang Department of Pharmacy, Yuli Hospital DOH Department of Pharmacology, Tzu Chi University April 20, 2013 Brief history of HGP 1953: DNA

More information

Part II of IV: Precision Medicine and Pharmacogenomics. How pharmacogenomics is improving patient care

Part II of IV: Precision Medicine and Pharmacogenomics. How pharmacogenomics is improving patient care Part II of IV: Precision Medicine and Pharmacogenomics How pharmacogenomics is improving patient care March 2018 Author Kelly Chillingworth, RPh, MHA/Ed, CGP Senior Pharmacy Consultant Lockton Benefit

More information

Pharmacogenomics within the EHR

Pharmacogenomics within the EHR Pharmacogenomics within the EHR Session #258, March 8, 2018 2:30 PM 3:30 PM Jon Walter McKeeby, DSc NIH CC CIO Jharana Tina Patel, PharmD, MBA, Pharmacy Information Officer 1 Conflict of Interest Jon Walter

More information

Introduction to Pharmacogenomics in Pharmacy Practice

Introduction to Pharmacogenomics in Pharmacy Practice Pharmacy Technician Education for Association Members By: Brad Tice PharmD, MBA, FAPhA Brad Tice received his bachelor of science in pharmacy from the University of Kansas in 1994 and his doctor of pharmacy

More information

Nanthealth Patient Informed Consent

Nanthealth Patient Informed Consent Patient Informed Consent Why am I being asked to give consent? You are being asked to sign this consent form because you want to have a molecular/genomic analysis performed to help your physician understand

More information

Slides are from Level 3 Biology Course Content Day, 7 th November Presenter: Justin O Sullivan

Slides are from Level 3 Biology Course Content Day, 7 th November Presenter: Justin O Sullivan Slides are from Level 3 Biology Course Content Day, 7 th November 2012 Presenter: Justin O Sullivan Teachers are free to use these for teaching purposes with appropriate acknowledgement Personalized genomics

More information

Clinical Applications in Pharmacogenomics/Genomic Medicine. Post-Course Survey

Clinical Applications in Pharmacogenomics/Genomic Medicine. Post-Course Survey Clinical Applications in Pharmacogenomics/Genomic Medicine Post-Course Survey Note: Students will be asked questions specific to the course in which they are enrolled. This is denoted throughout by use

More information

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient

More information

An innovative approach to genetic testing for improved patient care

An innovative approach to genetic testing for improved patient care An innovative approach to genetic testing for improved patient care Blueprint Genetics Blueprint Genetics is changing diagnostics by providing fast, affordable and comprehensive genetic knowledge Who we

More information

- OMICS IN PERSONALISED MEDICINE

- OMICS IN PERSONALISED MEDICINE SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary

More information

Pharmacogenomics in Pain Management

Pharmacogenomics in Pain Management WHITE PAPER Pharmacogenomics in Pain Management Personalized Pain Therapy Authors: ANDREW PURCHASE, BSc Associate Director, Safety & Risk Management PRA Health Sciences LYNN WEBSTER, MD Vice President,

More information

Informed Consent for Columbia Combined Genetic Panel (CCGP) for Adults Please read the following

Informed Consent for Columbia Combined Genetic Panel (CCGP) for Adults Please read the following Informed Consent for Columbia Combined Genetic Panel (CCGP) for Adults Please read the following form carefully and discuss with your ordering physician/genetic counselor before signing consent. 1. The

More information

Integrating Genomics in Family Medicine

Integrating Genomics in Family Medicine Lehigh Valley Health Network LVHN Scholarly Works Department of Family Medicine Integrating Genomics in Family Medicine Brian Stello MD Lehigh Valley Health Network, Brian.Stello@lvhn.org Follow this and

More information

AutoGenomics, Inc. COMPANY PROFILE. For reprint orders, please contact:

AutoGenomics, Inc. COMPANY PROFILE. For reprint orders, please contact: For reprint orders, please contact: reprints@future-medicine.co.uk COMPANY PROFILE AutoGenomics, Inc. Ram Vairavan Vice President, Marketing & Business Development 2270-K, Camino Vida Roble Carlsbad, CA

More information

REPRODUCTIVE HEALTH. Phosphorus. Diagnostics

REPRODUCTIVE HEALTH. Phosphorus. Diagnostics 14 32 6 32 7 REPRODUCTIVE HEALTH Phosphorus Diagnostics Genomics, Illuminated We focus on your peace of mind. Our expert-guided assay designs, powerful data analytics, and rigorous variant interpretation

More information

Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)

Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Strategies for modern biomarker and drug - Oct 3, 2014 Sequencing the cancer genome

More information

Exome Sequencing Exome sequencing is a technique that is used to examine all of the protein-coding regions of the genome.

Exome Sequencing Exome sequencing is a technique that is used to examine all of the protein-coding regions of the genome. Glossary of Terms Genetics is a term that refers to the study of genes and their role in inheritance the way certain traits are passed down from one generation to another. Genomics is the study of all

More information

Moving Medication to Market More Quickly

Moving Medication to Market More Quickly Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/moving-medication-to-market-more-quickly/1981/

More information

The Age of Personalised Medicine Are We Ready?

The Age of Personalised Medicine Are We Ready? CSO s Scientific Meeting, FCI, 7 th March 2017 The Age of Personalised Medicine Are We Ready? Phil Beales Professor of Medical and Molecular Genetics Head of UCL Personalized Medicine Domain UCL Great

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS CLINICAL TRIALS FREQUENTLY ASKED QUESTIONS PARTICIPATING IN A CLINICAL TRIAL What is a clinical trial? Clinical trials are research studies that involve people. Through clinical trials, researchers find

More information

The role of genomics in the development of new and improved therapies

The role of genomics in the development of new and improved therapies The role of genomics in the development of new and improved therapies An appreciation of the importance of genetic diversity will have a profound impact on how drugs are discovered, developed and prescribed.

More information

Introduction to Pharmacogenetics Competency

Introduction to Pharmacogenetics Competency Introduction to Pharmacogenetics Competency Updated on 6/2015 Pre-test Question # 1 Pharmacogenetics is the study of how genetic variations affect drug response a) True b) False Pre-test Question # 2 Pharmacogenetic

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_statin_induced_myopathy 01/01/2019 N/A 01/01/2020 01/01/2019 Description of Procedure

More information

RESPONSE TO RFP - Title Page

RESPONSE TO RFP - Title Page University of Pennsylvania RESPONSE TO RFP - Title Page Request for Proposal (RFP) Number: 002 Issue Date: July 16, 2008 Proposal Due Date: August 18 2008 Title of RFP: Central Laboratory for a Randomized

More information

Name: Name: PATIENT INFORMATION Patient's Last Name, First Name, MI Birthdate (mm/dd/yyyy) Gender

Name: Name:   PATIENT INFORMATION Patient's Last Name, First Name, MI Birthdate (mm/dd/yyyy) Gender TEST REQUISITION FORM (LAL DEFICIENCY) INCLUDE THE FIRST 3 PAGES OF THIS FORM WITH SPECIMEN. Before sending specimens, please contact us for pre-authorization procedures. Samples received without billing

More information

CRO partner in Rx/CDx Co-Development

CRO partner in Rx/CDx Co-Development CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics

More information

How Advances in Molecular Diagnostics Will Further Drive Consolidation of All Lab Testing. Executive War College 2013 New Orleans, LA

How Advances in Molecular Diagnostics Will Further Drive Consolidation of All Lab Testing. Executive War College 2013 New Orleans, LA How Advances in Molecular Diagnostics Will Further Drive Consolidation of All Lab Testing Executive War College 2013 New Orleans, LA Discussion Points What s driving consolidation? What is the relationship

More information

Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego

Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego Discuss the difference between DNA Genotyping and Genome Sequencing What makes you who you

More information

Genes & Medicine: How DNA is Improving Your Health

Genes & Medicine: How DNA is Improving Your Health Genes & Medicine: How DNA is Improving Your Health U3A Mountford, June 2004 Dr Martin Kennedy Department of Pathology Christchurch School of Medicine & Health Sciences University of Otago What this talk

More information

Personalized Healthcare Diagnostik und Therapie aus einer Hand

Personalized Healthcare Diagnostik und Therapie aus einer Hand Personalized Healthcare Diagnostik und Therapie aus einer Hand Priv.-Doz. Dr. med. Christian Meisel DVFA Life Science Conference, 17 June 2009 1 The Challenge Personalised healthcare Roche s unique position

More information

Adis Journals and Newsletters The premier collection of drug-focused medical journals

Adis Journals and Newsletters The premier collection of drug-focused medical journals adis.com Adis Journals and Newsletters The premier collection of drug-focused medical journals An invaluable resource for all involved in medical research, practice or teaching, drug regulation or reimbursement,

More information

A New Era of Clinical Diagnostics: How the Business Model is Changing.

A New Era of Clinical Diagnostics: How the Business Model is Changing. A New Era of Clinical Diagnostics: How the Business Model is Changing. Nancy J Kelley, President and CEO of Nancy J Kelley & Associates Remarks to BTIG Emerging Technologies in Healthcare Diagnostics September

More information

Pharmacogenomics and Health Policy

Pharmacogenomics and Health Policy Pharmacogenomics and Health Policy Amalia M. Issa, PhD, MPH Founding Director, Program in Personalized Medicine & Targeted Therapeutics Professor and Chair Department of Health Policy and Public Health

More information

Up Close and Personal

Up Close and Personal Special Report Up Close and With Personal advances in genetics, a new type of medicine has emerged: one that s tailored just for you and your DNA. Could it transform the paradigm of how we treat and prevent

More information

Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) READ ONLINE

Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) READ ONLINE Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) READ ONLINE to modify patients' exposure to drugs based on their genomic drug-response

More information

Bringing Home the Genome: the FDA s Role in Realizing Personalized Medicine Margaret Hamburg, M.D., FDA Commissioner

Bringing Home the Genome: the FDA s Role in Realizing Personalized Medicine Margaret Hamburg, M.D., FDA Commissioner 1 Bringing Home the Genome: the FDA s Role in Realizing Personalized Medicine Margaret Hamburg, M.D., FDA Commissioner February 25, 2010 I d like to thank the Personalized Medicine Coalition for inviting

More information

Chapter. Scientific background

Chapter. Scientific background Chapter Scientific background 2 Scientific background Introduction 2.1 This chapter explains how genetic variation can affect response to medicines, and uses case studies to illustrate how information

More information

The patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.

The patient must address the treating physician directly if he/she has any questions or requires information regarding the test results. Order Form 1. Ordering of the FoundationOne Service The FoundationOne Service comprises the genetic analysis of tumour tissue and the compilation of a comprehensive report on any mutations found in the

More information

Brain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers

Brain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers FACT SHEET 22 Clinical Trials: Questions and Answers What is a clinical trial? Clinical trials are research studies that answer scientific questions and try to find better ways to prevent, screen for,

More information

Towards a P4 Healthcare System: Predictive, Preventive, Personalized & Participatory

Towards a P4 Healthcare System: Predictive, Preventive, Personalized & Participatory Towards a P4 Healthcare System: Predictive, Preventive, Personalized & Participatory Bull, 2012 Natalia Jiménez Lozano Business Development Manager BULL e-health Consultancy & Business Solutions Tlf: 913939253

More information

PERSONALIZED MEDICINE & ADVANCES IN DRUG METABOLISM

PERSONALIZED MEDICINE & ADVANCES IN DRUG METABOLISM PERSONALIZED MEDICINE & ADVANCES IN DRUG METABOLISM BY ANDREW BRADFORD, PHD, CLINICAL TESTING LABORATORIES, BILL MASSEY, PHD, MYGENESRX, AND R. JAMES BENTLEY, GENERAL GENETICS CORPORATION 48 datia focus

More information

The PREDICT Program at Vanderbilt : Four Drug Gene Interactions and Counting

The PREDICT Program at Vanderbilt : Four Drug Gene Interactions and Counting The PREDICT Program at Vanderbilt : Four Drug Gene Interactions and Counting Michael Laposata, MD, PhD Fody Professor of Pathology Professor of Medicine Pathologist in Chief Vanderbilt University Hospital

More information

Specialty Pharmacy 101

Specialty Pharmacy 101 Specialty Pharmacy 101 The Landscape of Specialty Pharmacy Services DATE: October 27, 2011 NAME: TITLE: Clinical Pharmacist, Serve You Agenda Define specialty pharmacy Examine market trends and current

More information

Information Technology for Genetic and Genomic Based Personalized Medicine. Submitted. April 23, 2008

Information Technology for Genetic and Genomic Based Personalized Medicine. Submitted. April 23, 2008 Information Technology for Genetic and Genomic Based Personalized Medicine Submitted April 23, 2008 By The Harvard Medical School Partners HealthCare Center for Genetics and Genomics in Partnership with

More information

TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS

TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS THE DOORS ARE OPEN: FEEL FREE TO COME IN CENTOGENE UNLOCKS THE POWER OF GENETIC INSIGHTS TO IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH GENETIC

More information

OCREVUS Start Form. Instructions for Patients. Instructions for Health Care Providers

OCREVUS Start Form. Instructions for Patients. Instructions for Health Care Providers Instructions for Patients By completing this form: You will enroll in support services from Genentech You can apply to the Genentech Access to Care Foundation (GATCF) to determine if you are eligible to

More information

How Logistics Enables the Healthcare Revolution. Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company

How Logistics Enables the Healthcare Revolution. Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company How Logistics Enables the Healthcare Revolution Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company Introduction There is a revolution taking place in healthcare delivery. Patient-centred

More information

FDA s Critical Path Initiative and Drug Development

FDA s Critical Path Initiative and Drug Development FDA s Critical Path Initiative and Drug Development Duu-Gong Wu, PhD Executive Director, PharmaNet Consulting The views expressed herein are solely those of the author and do not necessarily reflect the

More information

Strategy resets to patient outcomes. The state of life sciences

Strategy resets to patient outcomes. The state of life sciences Strategy resets to patient outcomes The state of life sciences New innovative products, even at a high cost, can be a great deal for society and the health care system if they cure a chronic disease. Expensive

More information

Investing in Discovery

Investing in Discovery Investing in Discovery The Impact of Basic Research and the Role of the National Institute of General Medical Sciences Jeremy M. Berg, Ph.D. Director National Institute of General Medical Sciences National

More information

Innovative Approaches to Saving Patients Money on Prescription Drug Costs

Innovative Approaches to Saving Patients Money on Prescription Drug Costs Innovative Approaches to Saving Patients Money on Prescription Drug Costs April 2018 1 Innovative Approaches to Saving Patients Money on Prescription Drug Costs Executive Summary As prescription drug prices

More information

Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients

Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/centre-for-personalised-medicine-intuebingen-developing-tailor-made-treatments-for-patients/ Centre for Personalised Medicine

More information

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs

More information

Outline. Impact on Human Diseases Basis for Molecular Assay Novel Biomarkers

Outline. Impact on Human Diseases Basis for Molecular Assay Novel Biomarkers MOLECULAR DIAGNOSITICS 1 Outline Concept of Molecular Diagnostics History of Molecular Diagnostics Impact on Human Diseases Basis for Molecular Assay Novel Biomarkers 2 Molecular Diagnosis Molecular diagnosis

More information

September 8, General Comments:

September 8, General Comments: September 8, 2009 AMP Comments on the draft report from the Agency for Healthcare Research and Quality (AHRQ): AHRQ Draft Report on Quality, Regulation and Clinical Utility of Laboratorydeveloped Tests.

More information

Class Effects Definition? CLASS EFFECTS Rational Basis for Strength of Prediction. Drug Classes and Class Effects

Class Effects Definition? CLASS EFFECTS Rational Basis for Strength of Prediction. Drug Classes and Class Effects 1 CLASS EFFECTS Rational Basis for Strength of Prediction Acknowledgement: The ideas expressed here were developed in collaboration with Dr David Woolner. His broad knowledge of clinical pharmacology,

More information

A GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE

A GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE A GUIDE TO THIS REFLECTIONS B327-02 RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for

More information

Healthcare infrastructure and optimizing healthcare processes

Healthcare infrastructure and optimizing healthcare processes 1 Healthcare infrastructure and optimizing healthcare processes Dr. Karl-Jürgen Schmitt Siemens Medical Solutions Public Relation and Health Policy Siemens medical Solutions that help 2 Healthcare is one

More information

Comparative Effectiveness Research. Informing Public and Private Payer Decision-Making Brian Sweet, Chief Pharmacy Officer June 24, 2010

Comparative Effectiveness Research. Informing Public and Private Payer Decision-Making Brian Sweet, Chief Pharmacy Officer June 24, 2010 Comparative Effectiveness Research Informing Public and Private Payer Decision-Making Brian Sweet, Chief Pharmacy Officer June 24, 2010 How Evidence Begins No Evidence Beginning of Human Testing FDA Approval

More information

Each revolutionary change in

Each revolutionary change in The Art and Science of Personalized Medicine M Piquette-Miller and DM Grant If it were not for the great variability among individuals, medicine might as well be a science and not an art. Sir William Osler,

More information

About Clinical Trials: What They Can Mean For You?

About Clinical Trials: What They Can Mean For You? About Clinical Trials: What They Can Mean For You? Karl Cremer, PharmD and AnnKatrin Petersen, MD, MS January 25, 2012 ClinicalStudy.org Owned and operated by PRI, Inc. 5927 Balfour Court, Suite 201 Carlsbad,

More information

Prescription Medicines: Costs in Context

Prescription Medicines: Costs in Context Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical

More information

REPORT 4 OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH (A-10) Genomic-based Personalized Medicine (Reference Committee E) EXECUTIVE SUMMARY

REPORT 4 OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH (A-10) Genomic-based Personalized Medicine (Reference Committee E) EXECUTIVE SUMMARY REPORT OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH (A-) Genomic-based Personalized Medicine (Reference Committee E) EXECUTIVE SUMMARY Objectives. The term personalized medicine (PM) refers to health care

More information

Clinical and Research Questions

Clinical and Research Questions Health Record: The Next Leap Forward John Glaser, PhD Vice President and CIO Partners HealthCare May 8, 2008 Clinical and Research Questions Research Why do some patients with asthma respond to steroid

More information

COPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES

COPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES COPE CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES FAQs This brochure addresses FAQ and is prepared solely for the German market. Local adjustments may be necessary. Please contact us if you require additional

More information

Introduction to Pharmacogenomics

Introduction to Pharmacogenomics Introduction to Pharmacogenomics Ching-Lung Cheung, PhD Assistant Professor, Department of Pharmacology and Pharmacy, Centre for Genomic Sciences, HKU Overview of the lecture Overview of the lecture Introduction

More information

Megan Schmidt Vice President of Product Management, CompuGroup Medical

Megan Schmidt Vice President of Product Management, CompuGroup Medical Thursday April 6, 2017 A01 Molecular and Genetic Testing: How to Position your Laboratory for New Technology Megan Schmidt Vice President of Product Management, CompuGroup Medical DESCRIPTION: Molecular

More information

For more information about how to cite these materials visit

For more information about how to cite these materials visit Attribution: Kim Eagle, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Share Alike 3.0 License: http://creativecommons.org/licenses/by-sa/3.0/

More information

Human Genomics, Precision Medicine, and Advancing Human Health. The Human Genome. The Origin of Genomics : 1987

Human Genomics, Precision Medicine, and Advancing Human Health. The Human Genome. The Origin of Genomics : 1987 Human Genomics, Precision Medicine, and Advancing Human Health Eric Green, M.D., Ph.D. Director, NHGRI The Human Genome Cells Nucleus Chromosome DNA Human Genome: 3 Billion Bases (letters) The Origin of

More information

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities

More information

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics

More information

Preparing For A New Era of Medical Product Development

Preparing For A New Era of Medical Product Development Latham & Watkins Health Care & Life Sciences Practice Number 1607 November 7, 2013 Preparing For A New Era of Medical Product Development FDA report demonstrates support for personalized medicine and more

More information

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.

More information

Laboratory Stewardship - The Power of Appropriate Test Utilization

Laboratory Stewardship - The Power of Appropriate Test Utilization Laboratory Stewardship - The Power of Appropriate Test Utilization Suzanne Carasso, MBA, MT (ASCP) Director, Business Solutions Consulting ARUP Laboratories May 23, 2018 Copyright 2016, Cardinal Health.

More information

INTUITIVE, INTELLIGENT, INDIVIDUAL

INTUITIVE, INTELLIGENT, INDIVIDUAL INTUITIVE, INTELLIGENT, INDIVIDUAL About Yeats Clinical Yeats Clinical from Medicomp Solutions is a fully accredited web based software solution which integrates PM (Practice Management) and EHR (Electronic

More information

Personalized Medicine: The Changing Landscape of Health Care

Personalized Medicine: The Changing Landscape of Health Care Personalized Medicine: The Changing Landscape of Health Care The 2 nd Biomarker Meeting in Personalized Reproductive Medicine Valencia, Spain 11 April, 2014 Edward Abrahams, Ph.D. President Personalized

More information

Illumina Clinical Services Laboratory

Illumina Clinical Services Laboratory Illumina Clinical Services Laboratory CLIA Certificate No.: 05D1092911 Illumina Clinical Services Laboratory TruGenome Technical Sequence Data Test Requisition Form The Illumina Clinical Services Laboratory

More information

Outline. Genomics Medicine: Managing your own health. - Market overview: now and future. - What is genomic medicine?

Outline. Genomics Medicine: Managing your own health. - Market overview: now and future. - What is genomic medicine? Genomics Medicine: Managing your own health Mostafa Ronaghi SVP & CTO, Illumina Barcelona June 2013 2012 Illumina, Inc. All rights reserved. Illumina, illuminadx, BaseSpace, BeadArray, BeadXpress, cbot,

More information

Pharmacy Benefit Management (PBM) Overview

Pharmacy Benefit Management (PBM) Overview Pharmacy Benefit Management (PBM) Overview Agenda Introductions to ARMSRx Team & Services Stephanie Cormier Christine Heutinck The PBM history and role in healthcare CIS key performance indicators (KPIs)

More information

Introduction to Genetics and Pharmacogenomics

Introduction to Genetics and Pharmacogenomics Introduction to Genetics and Pharmacogenomics Ching-Lung Cheung, PhD Assistant Professor, Department of Pharmacology and Pharmacy, Centre for Genomic Sciences, HKU Survey on pharmacogenomic knowledge Survey

More information

Patenting personalised medicines in Europe. By Christian Heubeck and Wolfgang Weiss Weickmann & Weickmann

Patenting personalised medicines in Europe. By Christian Heubeck and Wolfgang Weiss Weickmann & Weickmann Patenting personalised medicines in Europe By Christian Heubeck and Wolfgang Weiss Weickmann & Weickmann Engineering Chemistry Life Sciences Trademarks Designs With the power of a globally acting law firm

More information

Policies Approved by the 2018 ASHP House of Delegates

Policies Approved by the 2018 ASHP House of Delegates House of Delegates Policies Approved by the 2018 ASHP House of Delegates 1801 Unit Dose Packaging Availability To advocate that pharmaceutical manufacturers provide all medications used in health systems

More information

FDA Regulation of Testing

FDA Regulation of Testing FDA Regulation of Testing Direct-to to-consumer Genetic Testing A Cross-Academies Workshop September 1, 2009 Courtney C. Harper, Ph.D. Office of In Vitro Diagnostic Device Evaluation and Safety Center

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Genetic Testing for Statin-induced Myopathy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_statin-induced_myopathy 6/2013 7/2017 7/2018

More information

Pharmacogenomics, Market Opportunities and Barriers. Presenter: Patrick J. Hurd, Esq. Senior Counsel Moderator: James P. Anelli, Esq.

Pharmacogenomics, Market Opportunities and Barriers. Presenter: Patrick J. Hurd, Esq. Senior Counsel Moderator: James P. Anelli, Esq. , Market Opportunities and Barriers Presenter: Patrick J. Hurd, Esq. Senior Counsel Moderator: James P. Anelli, Esq. Shareholder January 13, 2011 Today s presenters and some notes... Jim Anelli LeClairRyan

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Genetic Testing for Statin-induced Myopathy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_statin-induced_myopathy 6/2013 7/2018 7/2019

More information

Genomic Research: Issues to Consider. IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC

Genomic Research: Issues to Consider. IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC Genomic Research: Issues to Consider IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC Outline Key genomic terms and concepts Issues in genomic research Consent models Types of findings Returning results

More information

THE ERA OF INDIVIDUAL GENOMES. Sandra Viz Lasheras Advanced Genetics ( )

THE ERA OF INDIVIDUAL GENOMES. Sandra Viz Lasheras Advanced Genetics ( ) THE ERA OF INDIVIDUAL GENOMES Sandra Viz Lasheras Advanced Genetics (2017-2018) CONTENTS 1. INTRODUCTION - The genomic era - Sequencing techniques 2. PROJECTS - 1000 genomes project - Individual genome

More information

Genetics/Genomics in Public Health. Role of Clinical and Biochemical Geneticists in Public Health

Genetics/Genomics in Public Health. Role of Clinical and Biochemical Geneticists in Public Health Genetics/Genomics in Public Health Role of Clinical and Biochemical Geneticists in Public Health Premises Human variation is vast Strength of genetic factors are a continuum from low to high Testing technology

More information

CL1 : Molecular imaging for diagnosis and treatment of neurodegenerative disorders at a prodromal stage CL2 : The role of non-coding RNAs in

CL1 : Molecular imaging for diagnosis and treatment of neurodegenerative disorders at a prodromal stage CL2 : The role of non-coding RNAs in CL1 : Molecular imaging for diagnosis and treatment of neurodegenerative disorders at a prodromal stage CL2 : The role of non-coding RNAs in malignant cardiac diseases CL3 : Large scale optical imaging

More information

General News. Product Notes. Instrument Notice HELENA SALES FORCE TO: FROM: SUBJECT: HELENA POINT OF CARE ROUND-UP/US DOMESTIC DATE: 9/1/2009

General News. Product Notes. Instrument Notice HELENA SALES FORCE TO: FROM: SUBJECT: HELENA POINT OF CARE ROUND-UP/US DOMESTIC DATE: 9/1/2009 TO: FROM: SUBJECT: HELENA SALES FORCE DATE: 9/1/2009 General News HELENA POINT OF CARE ROUND-UP/US DOMESTIC We have concluded a very large meeting with the AACC in Chicago. The leads have been processed

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: clinical_trial_services 3/2002 2/2018 2/2019 8/2018 Description of Procedure or Service Clinical trials are

More information

Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology

Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology 9650 Rockville Pike, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7990 Email:

More information